Pyridam Farma Acquires Major Australian Pharmaceutical Company, Expands into Global Market.
Jakarta, August 9, 2024 – Anticipating the rapid growth of the health product market, PYFAGROUP, comprising leading pharmaceutical companies Pyridam Farma, Holi Pharma, Ethica Industri Farmasi, and Probiotec, is launching its Contract Development and Manufacturing Organization (CDMO) services. This strategic move aims to fulfill the industry’s demand for reliable and trustworthy production partners.
PYFAGROUP offers advanced production facilities and robust research and development (R&D) capabilities, supported by a team of seasoned experts from Indonesia and Australia. Our CDMO services encompass the entire product lifecycle, from initial formula development to commercialization, including product registration, mass production, and distribution.
With a strong track record and partnerships with industry giants such as Kalbe Farma, Dexa, Indocare, Nutrimax, Johnson & Johnson, Fresenius Kabi, and Arrowtech Pharmacare, PYFAGROUP has established itself as a trusted partner in the pharmaceutical industry. Our state-of-the-art facilities in Indonesia and Australia adhere to stringent local and international standards, ensuring the production of high-quality products to meet diverse consumer needs globally.
“The launch of our CDMO services is a pivotal step in solidifying PYFAGROUP’s position in the domestic and international markets,” said Savira Tjan, Head of COMO. “Our extensive production capacity, robust distribution network, and unwavering commitment to R&D will enable us to deliver exceptional solutions to our clients worldwide.”
Through CDMO services, PYFAGROUP seeks to foster closer collaborations with industry players, driving innovation and improving global healthcare outcomes.
